We use cookies on our site to analyze traffic, enhance your experience, and provide you with tailored content.

For more information visit our privacy policy.

Common use of Designation, Amount and Par Value Clause in Contracts

Designation, Amount and Par Value. The series of Preferred Stock shall be designated as the Corporation’s Series A Non-Voting Convertible Preferred Stock (the “Series A Non-Voting Preferred Stock”) and the number of shares so designated shall be 1,086,341. Each share of Series A Non-Voting Preferred Stock shall have a par value of $0.0001 per share.

Appears in 3 contracts

Samples: Merger Agreement (Spyre Therapeutics, Inc.), Merger Agreement (Aeglea BioTherapeutics, Inc.), Merger Agreement (Aeglea BioTherapeutics, Inc.)

Designation, Amount and Par Value. The series of Preferred Stock shall will be designated as the Corporation’s Series A Non-Voting Convertible Preferred Stock (the “Series A Non-Voting Preferred Stock”) and the number of shares so designated shall will be 1,086,3411,000, which will not be subject to increase without any consent of the holders of the Series A Preferred Stock (each a “Holder” and collectively, the “Holders”) that may be required by applicable law. Each share of Series A Non-Voting Preferred Stock shall will have a par value of $0.0001 0.001 per share.

Appears in 3 contracts

Samples: Stock Purchase Agreement (Cereplast Inc), Preferred Stock Purchase Agreement (Uluru Inc.), Preferred Stock Purchase Agreement (Uluru Inc.)

Designation, Amount and Par Value. The series of Preferred Stock shall be designated as the Corporation’s Series A Non-Voting Convertible Preferred Stock (the “Series A Non-Voting Preferred Stock”) and the number of shares so designated shall be 1,086,3412,270. Each share of Series A Non-Voting Preferred Stock shall have a par value of $0.0001 per share.

Appears in 2 contracts

Samples: Share Exchange Agreement (Virios Therapeutics, Inc.), Share Exchange Agreement (Virios Therapeutics, Inc.)

Designation, Amount and Par Value. The series of Preferred Stock shall be designated as the Corporation’s Series A Non-Voting Convertible Preferred Stock (the “Series A Non-Voting Preferred Stock”) and the number of shares so designated shall be 1,086,341[•]. Each share of Series A Non-Voting Preferred Stock shall have a par value of $0.0001 0.001 per share.

Appears in 1 contract

Samples: Merger Agreement (Aerovate Therapeutics, Inc.)

Designation, Amount and Par Value. The There shall be a series of Preferred Stock that shall be designated as the Corporation’s Series A Non-Voting Convertible Preferred Stock (the “Series A Non-Voting Preferred Stock” (the “Series A Preferred Stock”) and the number of shares so designated constituting such series shall be 1,086,341[●]. Each share of Series A Non-Voting Preferred Stock shall have a par value of $0.0001 0.001 per share. The shares of Series A Preferred Stock shall only be issued and maintained in the form of securities held in book-entry form.

Appears in 1 contract

Samples: Arrangement Agreement (Torchlight Energy Resources Inc)

Designation, Amount and Par Value. The series of Preferred Stock shall be designated as the Corporation’s Series A Non-Voting Convertible Preferred Stock (the “Series A Non-Voting Preferred Stock”) and the number of shares so designated shall be 1,086,341548,375. Each share of Series A Non-Voting Preferred Stock shall have a par value of $0.0001 per share.

Appears in 1 contract

Samples: Merger Agreement (Selecta Biosciences Inc)

Designation, Amount and Par Value. The series of Preferred Stock shall be designated as the Corporation’s Series A B Non-Voting Convertible Preferred Stock (the “Series A B Non-Voting Preferred Stock”) and the number of shares so designated shall be 1,086,341119,318.285. Each share of Series A B Non-Voting Preferred Stock shall have a par value of $0.0001 0.001 per share.

Appears in 1 contract

Samples: Agreement and Plan of Merger (Galera Therapeutics, Inc.)

Designation, Amount and Par Value. The series of Preferred Stock shall be designated as the Corporation’s Series A Non-Voting Convertible Preferred Stock (the “Series A Non-Voting Preferred Stock”) and the number of shares so designated shall be 1,086,341164,000. Each share of Series A Non-Voting Preferred Stock shall have a par value of $0.0001 0.001 per share. The shares of Series A Preferred Stock shall initially be issued and maintained in the form of securities held in book-entry form and the Depository Trust Company (“DTC”) or its nominee shall initially be the sole registered holder of the shares of Series A Preferred Stock.

Appears in 1 contract

Samples: Merger Agreement (Unum Therapeutics Inc.)

Designation, Amount and Par Value. The series of Preferred Stock shall be designated as the Corporation’s Series A X Non-Voting Convertible Preferred Stock (the “Series A Non-Voting X Preferred Stock”) and the number of shares so designated shall be 1,086,3415. Each share of Series A Non-Voting X Preferred Stock shall have a par value of $0.0001 0.01 per share.

Appears in 1 contract

Samples: Merger Agreement (Idera Pharmaceuticals, Inc.)

Designation, Amount and Par Value. The series of Preferred Stock shall be designated as the Corporation’s Series A Non-Voting Convertible Preferred Stock (the “Series A Non-Voting Preferred Stock”) and the number of shares so designated shall be 1,086,341435,000. Each share of Series A Non-Voting Preferred Stock shall have a par value of $0.0001 0.01 per share.

Appears in 1 contract

Samples: Merger Agreement (Miragen Therapeutics, Inc.)

Designation, Amount and Par Value. The A series of Preferred Stock shall be designated as the Corporation’s Series A Non-Voting Convertible Series A Preferred Stock (the "Series A Non-Voting Preferred Stock”) "), and the number of shares so designated shall be 1,086,34115,507. The par value of each share of Series A Preferred Stock shall be $0.001 par value. Each share of Series A Non-Voting Preferred Stock shall have a par stated value of $0.0001 32.25 per shareshare (the "Stated Value").

Appears in 1 contract

Samples: Settlement Agreement (Incomnet Inc)

Designation, Amount and Par Value. The series of Preferred Stock shall be designated as the Corporation’s Series A Non-Voting Convertible Preferred Stock (the “Series A Non-Voting Preferred Stock”) and the number of shares so designated shall be 1,086,3412,950,000. Each share of Series A Non-Voting Preferred Stock shall have a par value of $0.0001 0.001 per share. The shares of Series A Non-Voting Preferred Stock shall initially be issued and maintained in the form of securities held in book-entry form and the DTC or its nominee shall initially be the sole registered holder of the shares of Series A Non-Voting Preferred Stock.

Appears in 1 contract

Samples: Merger Agreement (Aprea Therapeutics, Inc.)

Designation, Amount and Par Value. The series of Preferred Stock shall be designated as the Corporation’s Series A X Non-Voting Convertible Preferred Stock (the “Series A X Non-Voting Preferred Stock”) and the number of shares so designated shall be 1,086,341[•]. Each share of Series A X Non-Voting Preferred Stock shall have a par value of $0.0001 0.01 per share.

Appears in 1 contract

Samples: Merger Agreement (Baudax Bio, Inc.)

Designation, Amount and Par Value. The series of Preferred Stock shall be designated as the Corporation’s Series A C Non-Voting Convertible Preferred Stock (the “Series A C Non-Voting Preferred Stock”) and the number of shares so designated shall be 1,086,34120,000. Each share of Series A C Non-Voting Preferred Stock shall have a par value of $0.0001 0.01 per share.

Appears in 1 contract

Samples: Merger Agreement (Traws Pharma, Inc.)